Synthetic Biologics Inc. (NYSEMKT: SYN) announced that enrollment has initiated and the first patient was dosed in a phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhoea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics Inc. (NYSEMKT: SYN) in last trading activity moved up 6.16% to close at $1.55. Company weekly performance is 6.16% while its quarterly performance stands at -8.28%. Synthetic Biologics Inc. (NYSEMKT: SYN) is -57.42% away from its 52 week high.
On 19 December SandRidge Mississippian Trust I (NYSE:SDR) announced its earnings results on Thursday. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.39 by $0.09. On last trading day SandRidge Mississippian Trust I (NYSE:SDT) moved up 15.23% to close at $3.48. Its volatility for the week is 7.42% while volatility for the month is 6.12%. SDT’s EPS growth for past 5 years was -23.61%. SandRidge Mississippian Trust I (NYSE:SDT) monthly performance is -4.40%.
On 23 December InterOil Corporation (NYSE:IOC) said it has started drilling the Antelope-5 appraisal well in Petroleum Retention License 15 in the Gulf Province of Papua New Guinea. InterOil Corporation (NYSE:IOC) has 4.47% insider ownership while its institutional ownership stands at 62.40%. In last trading activity company’s stock closed at $49.05.
On 18 December Fate Therapeutics, Inc. (NASDAQ:FATE) reported initial data from the first 12 subjects administered PROHEMA® in the Company’s ongoing Phase 2 PUMA study and announced that the study’s independent Data Monitoring Committee (iDMC) supported continuation of the clinical trial following a second planned interim safety review. On Friday shares of Fate Therapeutics, Inc. (NASDAQ:FATE) closed at $5.14.
JPMorgan Chase & Co. initiated coverage on shares of Tootsie Roll Industries Inc. (NYSE:TR) in a research report released on Tuesday morning. The firm issued a neutral rating and a $100.00 price objective on the stock. On last trading day Tootsie Roll Industries Inc. (NYSE:TR) decreased -1.21% to close at $30.28. Its volatility for the week is 1.70% while volatility for the month is 1.83%. TR’s sales growth for past 5 years was 1.80% and its EPS growth for past 5 years was 10.50%. Tootsie Roll Industries Inc. (NYSE:TR) monthly performance is 3.63%.